Gossamer Bio Reports Q1 GAAP EPS of -$0.20, Revenue Exceeds Expectations
Gossamer Bio reported a first-quarter GAAP earnings per share (EPS) loss of $0.20, missing estimates by $0.06. However, revenue reached $16.96 million, surpassing expectations by $13.14 million and growing 71.3% year-over-year.
Tickers: $GOSS
Topics: biotech financial_results pharma